Alopecia (hair loss) is loss of hair from part of the scalp or body and can range from small patches to diffuse or complete loss. Common forms include male/female pattern hair loss, alopecia areata, and telogen effluvium.
Sacituzumab tirumotecan demonstrated a median overall survival of 20.0 months versus 13.5 months with docetaxel in pretreated EGFR-mutated NSCLC patients. The phase 2 OptiTROP-Lung03 study showed a hazard ratio of 0.63 for overall survival benefit with the TROP2-directed antibody-drug conjugate.
The FDA has approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer based on trial data showing improved survival. Separately, the agency granted Breakthrough Therapy designation to Lilly's sofetabart mipitecan for the same condition, expediting development of the antibody-drug conjugate.
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
The FDA approved pembrolizumab in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1).
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen, for cancer patients at risk of infection due to chemotherapy and other indications. The approval marks Accord BioPharma's sixth biosimilar product.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07474558 |
SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates |
NOT_YET_RECRUITING | PHASE2 |
| NCT07428954 |
Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care |
COMPLETED | |
| NCT07422376 |
Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region |
RECRUITING | NA |
| NCT07271212 |
Scalp Care Efficacy Evaluation for Premium Revitalizing Elixir |
ACTIVE_NOT_RECRUITING | NA |
| NCT07228156 |
Study to Evaluate Xtresse Serum in Individuals With Thinning Hair |
ENROLLING_BY_INVITATION | NA |
| NCT07174011 |
Evaluation of the Efficacy and Safety of Oral Roflumilast Versus Intralesional Corticosteroids Injection (ILCs) in the Treatment of Alopecia Areata |
COMPLETED | PHASE4 |
| NCT07107841 |
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site) |
RECRUITING | NA |
| NCT07056933 |
Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia |
NOT_YET_RECRUITING | NA |
| NCT06999408 |
Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning |
ACTIVE_NOT_RECRUITING | NA |
| NCT06998680 |
6-Month Trial of Chinese Herbal Treatments for Hair Loss and Gray Hair |
RECRUITING | NA |
